Introduction
Though vincristine therapy is commonly complicated by a peripheral neuropathy (Finkel, 1967) central nervous system effects have been less frequently reported. Coma is particularly uncommon (Kleinknecht et al., 1967; Loo and Zittoun, 1969; Johnson et al., 1973) and in some patients it has been associated with hyponatraemia ascribed to inappropriate secretion of antidiuretic hormone (Fine et al., 1966; Slater et al., 1969) . We report here three further patients with reversible coma after vincristine therapy, one of whom was also noted to have hyponatraemia during the period of unconsciousness.
Case 1
A 65-year-old man was admitted to the University Hospital of Wales on 24 April 1973 with a one-month history of increasing shortness of breath. On examination he was pyrexial (temperature 38 5°C) and a pleural rub was audible at the left base. There was mod-erate hepatosplenonegaly but no purpura or lymphadenopathy, and a full examination of the central nervous system showed nothing abnormal. Investigations were Hib 9.3 g/ 100 ml, W.B.C.
15,600/mm3 (23% blasts, 55% atypical monocytes), and platelets 42,000/mnm3. A chest x-ray picture showed diffuse bilateral nodular opacities and a small pleural effusion at the left base. Blood and sputum cultures were sterile. Bone marrow examination confirmed a diagnosis of acute leukaemia of undifferentiated cell type.
Treatment was started on the third hos,pital day with cyclophosphamide (200 mg/m2 given intravenously). Next day he was given vincrinstine intravenously (10 mg/m2, total dose 1-75 mg) and started on cytosine arabinoside (280 mg/mm given intravenously 12-hourly for two days) and prednisone (40 mg/m2 by mouth for five days). He remained well until the 12th hospital day when he became comatose. Next day he was just rousable, but incoherent and disorientated; he remained in this state for 11 days, when consciouness fully returned. Throughout this period there was no clinical evidence of focal neurological abnormality ,and cerebrospinal fluid examination showed nothing abnormal. An (Costa et al., 1962) , and autonomic dysfunction (Finkel, 1967) are somewhat less frequent, and irritability (Council on Drugs, 1965), mental depression (Karon et al., 1962) , convulsions (Kleinknecht et al., 1967; Grobe and Palm, 1972; Johnson et al., 1973) , and coma (Kleinknecht et al., 1967; Loo and Zittoun, 1969; Slater et al., 1969) are rare. In several ways the cases reported here resemble other reported cases of coma or convulsions after vincristine therapy. The onset is usually a few days after an injection of vincristine recovery seems to be complete and, as shown by case 2, further treatment with vincristine may be tolerated without recurrence (Johnson et al., 1973) . Furthermore in a proportion of patients coma or convulsions have been associated with hyponatraemia (Fine et al., 1966; Loo and Zittoun, 1969; Slater et al., 1969) and this has been ascribed to inappropriate secretion of antidiuretic hormone (Slater et al., 1969) .
The mechanism of coma after vincristine therapy remains obscure. In no patients so far described have focal neurological lesions been substantiated, and though no deaths have occurred from this complication, postmortem examination of patients who have died subsequently has been consistently unhelpful. Indeed vincristine has been implicated as a cause of coma and convulsions as much through a lack of other demonstrable cause as through an appreciation of its other, more substantiated, neurological side effects.
The suggestion that inappropriate antidiuretic hormone secretion occurs in a proportion of patients suggests either that two separate mechanisms are involved or that a single mechanism may be operative at the cellular level producing different clinical effects depending on the susceptibility of the various cells involved. This latter possibility may explain the development of coma in some and convulsions in others, and hyponatraemia in some patients from both groups. The duration of hyponatraemia is much shorter than that associated with inappropriate secretion of antidiuretic hormone from other causes (Haden and Knox, 1965) believed to ascend from the vagina. Cases of yeast fungus septicaemia during pregnancy are probably extremely rare. However, they present great therapeutic problems, as the antimycotic drugs available-above all amphotericin B-are so toxic that their use involves a great risk for the patient and probably an even greater risk for the fetus.
We recently treated a case of Candida albicans septicaemia during pregnancy successfully with 5-fluorocytosine (5-FC).
Case Report A 22-year-old woman suffered from hyperemesis gravidarum during her first pregnancy in 1970 which ended in spontaneous abortion. In 1971 she was again pregnant, having had her last menstruation on 3 November 1971. At the end of December she suffered from a pronounced hyperemesis gravidarum, which necessitated admittance to hospital. Her symptoms grew worse and intravenous nutrition had to be given. A central venous catheter was placed in the superior vena cava and remained there until 22 February 1972. At the end of January 1972 she got septic fever. Ampicillin was given intravenously, and the temperature was temporarily reduced. On 9 February, however, she got chills and rising septic fever. Cloxacillin treatment was then instituted. Blood culture at that time showed a pure culture of C. albicans, and oral nystatin treatment, 1,000,000 I.U. three times daily, was started. The fever was slightly reduced, but on 16 February the patient again got chills and her general condition was strongly affected. Again blood culture showed a pure culture of C. albicans. The Yeast fungus septicaemia during early pregnancy is probably not a common condition. In reviewing the literature we have found only one similar case. This also occurred in connexion with a severe hyperemesis which necessitated intravenous nutrition. To save the patient first an abortion was induced and then amphotericin B treatment given. In this case the fungus was Torulopsis glabrata (Hahn et al., 1968) .
In these cases the problem of appropriate treatment is a very difficult one. Until now there has been nothing but amphotericin B treatment to be given. This preparation is effective against the fungus, but it is so toxic that many physicians hesitate to give it to children (Holt and Newman, 1972) . If it has to be given to a pregnant woman it therefore seems reasonable to induce an abortion because of the toxicity of the drug. This should be done when the patient's fungus septicaemia has been cured and her general condition has improved.
5-FC has proved to be an excellent antimycotic drug (Scholer, 1970; Schonebeck, 1971 Schonebeck, , 1972 with few and as a rule not serious side effects. However, Bennett (1971) and R. Y. Cartwright (personal communication, 1972) have reported bone marrow and liver toxicity. The teratogenic effects of 5-FC have been studied by Chaube and Murphy (1969) . They found that intraperitoneal administration of 500-4,000 mg/kg body weight to rats on the 11th or 12th day of gestation resulted in fetal deformities-mostly cleft palates, micrognathia, and short, kinky tails. If the drug was administered on the 9th or 10th day there were no deformities. The lowest teratogenic dose was 700 mg/kg body weight. The therapeutic dose of 5-FC in normal kidney function is about 50 mg/kg body weight every
